TLX Stock: 15% Gain, $30 Target & Valuation Analysis | Telix Pharmaceuticals

Telix Pharmaceuticals Sees Stock Jump on Strong Revenue and Positive Outlook

Shares of radiopharmaceutical company Telix Pharmaceuticals Limited (TLX) experienced a significant increase, rising nearly 15% on February 20, 2026, following the release of strong 2025 financial results and optimistic revenue projections for 2026. The company also filed a shelf registration to support future growth initiatives.

Telix reported full-year 2025 revenue of approximately $804 million, representing a substantial 56% increase compared to the previous year. This figure aligns with previously upgraded guidance provided by the company. Fourth-quarter 2025 group revenue reached around $208 million, a 46% increase year-over-year, driven by growing demand for Telix’s precision imaging products.

A key driver of this growth has been the successful U.S. Launch of Gozellix, Telix’s second prostate cancer imaging agent. The positive impact of Medicare reimbursement, which took effect in October 2025, contributed significantly to Gozellix’s uptake. The Precision Medicine segment generated approximately $161 million in Q4 revenue, a modest quarter-over-quarter increase, but benefiting from favorable pricing and product mix despite only a 3% increase in dose volumes.

Looking ahead to 2026, Telix management anticipates group revenue to fall between $950 million and $970 million. This projection suggests a mid-teens growth rate building upon the strong performance of 2025, and reflects continued adoption of both Illuccix and Gozellix, alongside planned geographic expansion.

Despite the positive revenue trends, profitability remains a challenge for Telix. The company reported 2025 operating income of approximately $19 million, a decrease from roughly $56 million in 2024. This decline is attributed to increased investments in research and development (R&D) and commercialization efforts across its therapeutic and manufacturing platforms.

Telix is actively advancing its pipeline, including a marketing application in Europe for TLX101-Px, an imaging agent for brain cancer, and ongoing late-stage development of TLX591 and other oncology candidates.

Currently, TLX shares are trading at $7.69 as of February 20, 2026, significantly below its 52-week high of $30.36. However, analysts maintain a positive outlook, with an average price target of $30.84, suggesting substantial potential upside.

Analysts covering the stock offer a consensus rating of “Strong Buy.” Data indicates a three-year compound revenue growth rate of 95.6%, with expectations for a forward two-year revenue CAGR of approximately 16.2% and an EBITDA CAGR exceeding 60% as operating leverage improves.

Investors should be aware of ongoing legal challenges. A securities fraud class action lawsuit, filed in late 2025, alleges that Telix overstated its progress in prostate cancer therapeutic candidates and the strength of its supply chain. The company disputes these claims.

The company’s valuation, while down from previous highs, remains at premium multiples. Future stock performance will likely depend on Telix achieving its 2026 revenue guidance, successfully navigating pipeline developments, and resolving legal and financing uncertainties without significantly diluting existing shareholders.

The market is closely watching Telix’s ability to translate its revenue growth into sustained profitability and to successfully execute its long-term strategy in the rapidly evolving field of radiopharmaceuticals.